Life Care News
A Hope Of True Information

Managers’ transactions – Eija Ronkainen


1 JUNE 2023 at 18.45 EEST

Orion Corporation: Managers’ transactions – Eija Ronkainen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj – Managers’ Transactions
Person subject to the notification requirement
Name: Eija Ronkainen
Position: Member of the Board/Deputy member
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Reference number: 32731/5/6
Transaction date: 2023-06-01
Outside a trading venue
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: PLEDGING
Transaction details
(1): Volume: 280000 Unit price: 0.0 EUR
Aggregated transactions (1):
Volume: 280000 Volume weighted average price: 0.0 EUR

- Advertisement -

Orion Corporation

Liisa Hurme

President and CEO

   Olli Huotari

SVP, Corporate Functions



Orion Corporation
Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion’s net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

Get real time updates directly on you device, subscribe now.

Has Aji River now become a dumping site?